Skip to content
Oncology Research Hub

Philadelphia, Pennsylvania

Cancer clinical trials in Philadelphia, PA

296 cancer studies are recruiting participants at sites in Philadelphia as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Philadelphia at a glance

  • 296 studies are recruiting at a site in Philadelphia.
  • By phase: Early Phase 1 (5), Phase 1 (50), Phase 1/2 (50), Phase 2 (48), Phase 2/3 (8), Phase 3 (65), Phase 4 (3), No phase (29), Observational (38). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (142), university, hospital or other (136), government (18).
  • By research area: Lung Cancer (76), Lymphoma (72), Breast Cancer (70), Prostate Cancer (33), Pancreatic Cancer (23), Melanoma (22).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in Philadelphia

Basic details from each study's public record (the 30 most recently updated of 296). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Fox Chase Cancer Center · Pennsylvania Hospital · Thomas Jefferson University Hospital
    Registry record
    NCT05564377 · updated
  2. S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Thomas Jefferson University Hospital
    Registry record
    NCT03723928 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Philadelphia, PA on ClinicalTrials.gov.

Lung cancer studies recruiting in Philadelphia

  1. LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    NovoCure GmbH
    Study site
    Abramson Cancer Center
    Registry record
    NCT06216301 · updated
  2. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University
    Registry record
    NCT07277413 · updated
  3. A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Perelman Center for Advanced Medicine ( Site 3205)
    Registry record
    NCT07513376 · updated
  4. Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Abramson Cancer Center at Penn Medicine
    Study site
    Abramson Cancer Center of the University of Pennsylvania
    Registry record
    NCT03760575 · updated
  5. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Fox Chase Cancer Center · Temple University Hospital · Thomas Jefferson University Hospital
    Registry record
    NCT04267848 · updated
  6. Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Fox Chase Cancer Center · Temple University Hospital
    Registry record
    NCT04665739 · updated
  7. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    ECOG-ACRIN Cancer Research Group
    Registry record
    NCT06096844 · updated
  8. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Jefferson Torresdale Hospital · Thomas Jefferson University Hospital
    Registry record
    NCT06498635 · updated
  9. Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Hospital of the University of Pennsylvania
    Registry record
    NCT07100080 · updated
  10. A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kestrel Therapeutics, Inc.
    Study site
    Sidney Kimmel Cancer Center
    Registry record
    NCT07458347 · updated
  11. RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

    • Phase 2
    • Ages 18 to 80
    • All sexes
    Sponsor
    Reunion Neuroscience Inc
    Study site
    University of Pennsylvania
    Registry record
    NCT07002034 · updated
  12. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    Univ of Pennsylvania, Abramson Cancer Center
    Registry record
    NCT07020221 · updated
  13. Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

    • Phase 1/2
    • Ages 12 to 85
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Hospital of the University of Pennsylvania
    Registry record
    NCT04959175 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Philadelphia, PA on ClinicalTrials.gov.

Prostate cancer studies recruiting in Philadelphia

  1. Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

    • Phase 2
    • Ages 18 and older
    • Male participants
    Sponsor
    VA Office of Research and Development
    Study site
    Philadelphia MultiService Center, Philadelphia, PA
    Registry record
    NCT04038502 · updated
  2. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    Penn Presbyterian Medical Center · Thomas Jefferson University Hospital · University of Pennsylvania/Abramson Cancer Center
    Registry record
    NCT04423211 · updated
  3. Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Amgen
    Study site
    Thomas Jefferson University
    Registry record
    NCT04221542 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Philadelphia, PA on ClinicalTrials.gov.

Melanoma studies recruiting in Philadelphia

  1. Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

    • Phase 3
    • Ages 75 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    Fox Chase Cancer Center · Thomas Jefferson University Hospital
    Registry record
    NCT07068074 · updated
  2. Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    Wills Eye Hospital at Thomas Jefferson University
    Registry record
    NCT07804186 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Philadelphia, PA on ClinicalTrials.gov.

Lymphoma studies recruiting in Philadelphia

  1. A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

    • Phase 1
    • Ages 0 to 18
    • All sexes
    Sponsor
    Autolus Limited
    Study site
    Children's Hospital of Philadelphia
    Registry record
    NCT06173518 · updated
  2. A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Abramson Cancer Center and Perelman Center for Advanced Medicine ( Site 0131) · Temple University Hospital ( Site 0133)
    Registry record
    NCT06890884 · updated
  3. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Jefferson Torresdale Hospital · Thomas Jefferson University Hospital
    Registry record
    NCT04269902 · updated
  4. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Children's Hospital of Philadelphia · Saint Christopher's Hospital for Children
    Registry record
    NCT04546399 · updated
  5. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Children's Hospital of Philadelphia · Saint Christopher's Hospital for Children · Thomas Jefferson University Hospital
    Registry record
    NCT05675410 · updated
  6. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Fox Chase Cancer Center · Thomas Jefferson University Hospital
    Registry record
    NCT06337318 · updated
  7. A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

    • Phase 3
    • Ages 1 and older
    • All sexes
    Sponsor
    Memorial Sloan Kettering Cancer Center
    Study site
    Children's Hospital of Philadelphia
    Registry record
    NCT07223021 · updated
  8. Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Thomas Jefferson University Hospital
    Registry record
    NCT06649812 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Philadelphia, PA on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Philadelphia

  1. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study sites
    Investigative Site US008 · Investigative Site US043
    Registry record
    NCT07522073 · updated
  2. APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Pennsylvania/Abramson Cancer Center
    Registry record
    NCT04858334 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Philadelphia, PA on ClinicalTrials.gov.

Ask about studies near Philadelphia

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Pennsylvania

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call